The stakes are enormous. Cancer affects roughly 20 million people each year, and projections suggest the annual burden could climb to 30.5 million by 2050. While tumor-intrinsic factors such as mutations and dysregulated signaling pathways remain central to oncology, researchers increasingly recognize that tumor-extrinsic factors, including everything non-cancerous within the tumor microenvironment and the broader tumor macroenvironment, powerfully influence disease trajectories. The cancer microbiome, spanning both the gut microbiome and the tumor-associated microbiome, has emerged as one of the most intriguing of these factors. Early studies focused on colorectal cancer simply because of anatomical proximity, but evidence now shows the gut microbiome acts systemically, modulating host immunity and metabolism across the body, and has been implicated in tumorigenesis, progression, treatment response, and immune-related adverse events.

The tumor-associated microbiome tells a different story. Unlike the gut’s rich microbial communities, intratumoral microbes exist in low abundance, sparse populations that vary dramatically by cancer type. Tumors exposed to the external environment, such as colorectal, gastric, and oral cancers, harbor relatively more microbial biomass, while pancreatic, liver, lung, and breast tumors are considered low-biomass settings. Evidence from experimental models and human datasets has linked these intratumoral communities to cancer progression, prognosis, and treatment response, and the microbes can localize both outside and inside cancer and immune cells, sometimes with distinct spatial organization. They influence their surroundings through infection, inflammation, and the production of metabolites, yet separating genuine microbial signals from laboratory contaminants remains one of the field’s hardest problems.

Computationally, the field has traveled a long road. Early studies relied on classical statistical tools such as differential abundance methods, including LEfSe and metagenomeSeq, to identify taxa associated with cancer risk, survival, and treatment response. But microbiome data are notoriously difficult: high-dimensional, sparse, zero-inflated, and compositional, properties that can reduce reproducibility. Network-based approaches like SparCC, CoNet, and SPIEC-EASI extended the toolkit by modeling microbial interactions and identifying community structures linked to cancer processes, yet they struggle with complex nonlinear relationships. Deep learning has now entered the picture, enabling integration of microbiome and multi-omics data to model higher-order interactions and improve biomarker discovery and clinical outcome prediction. The catch is that most AI models must work with high-dimensional but small-sample datasets, raising overfitting risks and threatening biomarker stability, especially without strong external or prospective validation.

Generating reliable data is the first battleground. Cancer microbiome studies produce diverse data types, each capturing different aspects of microbial composition, function, and host interaction. Partial 16S rRNA sequencing is affordable but usually resolves taxonomy only to the genus level; full-length 16S improves resolution to species; shotgun metagenomics captures all genes in a sample, enabling both taxonomy and functional prediction. Metatranscriptomics captures real-time gene expression but is technically demanding, limited by RNA instability and stringent handling requirements. Metaproteomics, which profiles expressed proteins, offers a more direct functional view but has barely touched cancer: a PubMed search as of June 2026 identified only nine cancer microbiome metaproteomics studies. Metabolomics rounds out the picture, measuring the small molecules microbes produce, with databases such as MiMeDB, the Natural Products Atlas, and MASST helping to attribute metabolites to microbial origins, while spatial metabolomics now maps region-specific metabolic changes within tumors.

Detecting intratumoral microbes demands special tools. Researchers have reanalyzed bulk RNA-seq and whole-genome sequencing data to infer microbial signals from non-human reads, but this approach is vulnerable to contamination, and a recent large-scale tumor whole-genome analysis found that after host subtraction and decontamination, detectable microbiome signals were largely restricted to orodigestive cancers. Specialized pipelines have emerged to help: CSI_Microbe extracts microbial reads from The Cancer Genome Atlas sequencing data, SAHMI denoises microbial signals from single-cell RNA sequencing, and INVADEseq adds a primer targeting the conserved 16S region to map microbes within individual human cells. Spatial technologies such as imaging mass cytometry with mass-tagged antibodies and desorption electrospray ionization mass spectrometry imaging can visualize microbial presence alongside host immune and tumor cells. The review also lays out practical standards for credible signals: negative controls, conservative host-read subtraction, evaluation of batch structure, and orthogonal validation through qPCR, culture, in situ hybridization, or spatial imaging.

Once data are trustworthy, AI modeling begins in earnest, and the review offers a sobering lesson: bigger is not always better. Benchmarking studies show that classical, regularized models remain strong baselines. In a 16S rRNA benchmark with 490 subjects and 6,920 features, L2-regularized logistic regression matched random forest performance while training faster and remaining more interpretable. A larger benchmark across 83 gut microbiome cohorts and 20 diseases found ridge regression and random forest among the best performers, with neural networks and gradient boosting not consistently outperforming them. Deep learning architectures, including multilayer perceptrons, transformers, graph neural networks, and autoencoders, expand modeling capacity for nonlinear and structure-aware analysis, and foundation models pretrained on large-scale microbiome data, such as MGM, GenomeOcean, and Evo2, promise transferable representations, but fine-tuning on small cancer cohorts still risks overfitting, and interpretability remains limited.

The applications are already impressive. Multi-view deep learning frameworks distinguish metastatic from non-metastatic colorectal cancer using gut microbial features, while methods like GDmicro combine graph convolutional networks with domain adaptation to improve cross-cohort robustness against differences in region, diet, and sequencing protocols. Integration frameworks such as VTrans use large-scale pretraining and selective co-attention to combine microbiome features with host transcriptomics and copy-number profiles, enhancing survival risk stratification in small cohorts. Interpretability methods, from SHAP values and integrated gradients to graph-based community explanations like Micah, are evolving from simple feature ranking toward direction-aware, network-level insights. Looking ahead, causal AI frameworks such as DAG-deepVASE, which combines deep networks with knockoff features to identify nonlinear causal relationships, could move the field beyond pure association, though the review stresses that such findings remain hypothesis-generating until validated.

Mechanistic evidence is accumulating for real biological effects. Intratumoral Fusobacterium nucleatum has been implicated in promoting tumor progression, metastasis, and chemoresistance through immune modulation, autophagy activation, and oncogenic signaling, while enterotoxigenic Bacteroides fragilis promoted tumorigenesis and metastasis in breast cancer models. Gut microbes directly metabolize therapeutic drugs: bacterial β-glucuronidase reactivates the inactive metabolite of irinotecan in the gut, causing diarrhea, and inhibiting this enzyme can preserve drug efficacy while limiting toxicity. In immunotherapy, antibiotic use before immune checkpoint inhibitor treatment is associated with poorer response and survival, fecal microbiota transplantation from responders enhances anti-PD-1 responses in preclinical models, and findings from the CIAO clinical trial showed that total intratumoral bacterial abundance was the only microbiome-related feature predicting immune checkpoint blockade response in head and neck cancer, with higher abundance linked to an immunosuppressive microenvironment.

Translating these discoveries into the clinic is the final and steepest climb. The review emphasizes a three-stage evidentiary hierarchy, analytical validation, clinical validation, and demonstrated clinical utility, that most cancer microbiome biomarkers have not yet climbed. Fecal metagenomic classifiers for colorectal cancer are the most mature, retaining accuracy around an AUC of 0.8 in independent cohorts, while tumor-intrinsic signatures have faced serious challenges over host-read misclassification and normalization artifacts. Interventional strategies show encouraging but preliminary signals, with responder-derived fecal transplants reinstating anti-PD-1 responses in some ICI-refractory melanoma patients, yet a fatal transmission of a drug-resistant bacterium during fecal transplantation underscores the safety stakes. The path forward, the authors argue, requires standardized reporting under frameworks like STORMS, contamination-aware pipelines, prospective multicenter validation, and AI systems treated as prioritization tools rather than oracles. Emerging paradigms, including agentic AI systems like Eubiota, human-in-the-loop frameworks, and digital twin approaches, may eventually knit microbiome data into iterative clinical translation, but only if every model is paired with uncertainty estimation and external validation. The era of the cancer microbiome is no longer a question of whether microbes matter in oncology, but of whether the field can prove it rigorously enough for patients to benefit.

Subject of Research: Integration of multi-omics technologies and artificial intelligence for decoding the cancer microbiome and translating discoveries into clinical oncology applications

Article Title: Decoding the cancer microbiome: multi-omics, AI, and translational opportunities

Article References: Decoding the cancer microbiome: multi-omics, AI, and translational opportunities. (n.d.). https://doi.org/10.1186/s13059-026-04284-8

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04284-8

Keywords: cancer microbiome, tumor-associated microbiome, gut microbiome, multi-omics, artificial intelligence, deep learning, biomarker discovery, immunotherapy response, Fusobacterium nucleatum, metagenomics, precision oncology, clinical translation

The mechanism centers on a molecule called MR1, a protein displayed on the surface of antigen-presenting immune cells. These cells, which include dendritic cells and macrophages, normally process molecular signals from microbes or damaged tissue and use surface proteins to alert specialized lymphocytes. MR1 is unusual because it presents small molecules produced during the synthesis and breakdown of vitamin B2, also known as riboflavin. MAIT cells carry receptors specifically adapted to recognize these MR1-bound metabolites, allowing them to respond rapidly to bacterial activity. Unlike conventional T cells, which often recognize highly individualized protein fragments, MAIT cells are tuned to a relatively conserved microbial pathway.

The Johns Hopkins researchers focused on a vitamin B2 metabolite known to interact with the MR1-MAIT cell system. In laboratory experiments, they combined the metabolite with bacteria isolated or identified in lung tumors and observed a marked increase in MR1 expression on antigen-presenting cells. Higher levels of MR1 created more molecular platforms through which MAIT cells could be stimulated. Once activated, MAIT cells can release inflammatory signaling proteins, including interferon-gamma and tumor necrosis factor, and can develop cytotoxic activity that enables them to attack abnormal cells. The study therefore points to a two-part biological trigger: bacteria provide the surrounding microbial context, while the metabolite helps raise the visibility of that context to the immune system.

The result was unexpected because the investigators initially assumed that the most effective bacteria would be those capable of producing vitamin B2 metabolites themselves. Instead, one strain of Enterococcus that did not produce the relevant metabolite substantially enhanced MAIT cell activation when the metabolite was added to cell cultures. This observation indicates that tumor-associated microbes may influence immunity without directly supplying the activating compound. Bacteria can alter the behavior of neighboring cells through surface structures, secreted products, nutrient consumption and inflammatory signals. In this case, the enterococcal species appeared to create conditions in which the vitamin B2 metabolite could more effectively increase MR1 expression and promote communication between antigen-presenting cells and MAIT cells.

The discovery emerged from an interdisciplinary analysis that combined microbiome sequencing, RNA sequencing of immune cells from patient samples and controlled cell culture experiments. By examining the bacterial communities present in human lung tumors alongside gene-expression patterns in immune cells, the researchers found evidence that the microbial composition of the tumor could be linked to regulation of the MR1 pathway. These findings are important because solid tumors are not sterile masses of cancer cells. They contain immune cells, blood vessels, connective tissue, metabolites and, in many cases, complex microbial communities. Those communities may shape whether the tumor microenvironment suppresses immune activity or permits immune cells to recognize and attack malignant tissue.

MAIT cells have received less attention in oncology than the conventional T cells targeted by many modern immunotherapies. Immune checkpoint inhibitors, including drugs that block the PD-1 pathway, are designed to release inhibitory signals that restrain adaptive T cells. When successful, this treatment can restore the ability of those cells to recognize tumor-associated antigens and kill cancer cells. MAIT cells belong to a different branch of immune defense. They are abundant in tissues exposed to the outside environment, such as the lungs and intestines, where they act as rapid responders to infection or injury. Their semi-invariant T-cell receptors allow them to recognize microbial metabolites presented by MR1 rather than the highly variable peptide antigens recognized by most adaptive T cells.

Evidence from patient samples provided an additional clue about the possible relevance of the pathway. In an earlier study of people with lung cancer who received neoadjuvant PD-1 blockade before surgery, Pakhi Birla, who led the new work during her doctoral research, examined immune features associated with treatment response. One patient who responded particularly well had a large population of MAIT cells in the tumor. This observation does not establish that MAIT cells caused the response, but it is consistent with the possibility that these cells contribute to effective immunotherapy in at least some tumors. The new laboratory findings offer a potential explanation for how bacterial signals could help activate MAIT cells within the tumor microenvironment.

The investigators are now conducting studies in mice to determine whether delivering the vitamin B2 metabolite directly into lung tumors can produce a measurable immune response. Such experiments will be necessary to establish whether the pathway can influence tumor growth, whether activated MAIT cells can reach and destroy cancer cells, and whether the treatment can be administered safely. A metabolite that stimulates immune activity in a culture dish may behave differently in a living organism, where it could be rapidly degraded, distributed to healthy tissues or blocked by the tumor’s immunosuppressive environment. The researchers will also need to determine which bacterial species, combinations of species or bacterial products are required for the response.

A second direction involves engineering T cells to recognize MR1. Current cell-based immunotherapies, such as some forms of engineered T-cell therapy, generally require receptors that target antigens differing among patients and tumor types. Because MR1 is expressed across many human tissues and presents metabolites from a conserved biochemical pathway, an MR1-directed therapy could, in principle, have broader application than highly personalized approaches. However, this possibility carries substantial safety challenges. MR1 is found on normal cells, and an engineered immune cell that recognizes MR1-associated signals must distinguish malignant tissue from healthy tissue. Before any human trial could be considered, researchers would need to demonstrate precise tumor selectivity, control excessive inflammation and prevent damage to essential organs.

The study’s authors emphasize that the work represents a new immunotherapy concept rather than an established cancer treatment. Its central insight is that tumor-associated bacteria may regulate immune surveillance by controlling how strongly antigen-presenting cells display MR1, while vitamin B2 metabolites provide the biochemical signal that activates MAIT cells. If future animal studies and clinical research confirm the effect, the approach could eventually complement checkpoint inhibitors or other immunotherapies by engaging an underused arm of the immune system. The long-term vision is a broadly applicable, potentially off-the-shelf treatment that does not need to be individually customized for every patient. For now, the results deepen scientists’ understanding of the tumor microbiome and reveal another way that microbial chemistry may determine whether the immune system sees cancer as a threat.

Subject of Research: Tumor-associated bacteria, vitamin B2 metabolites, MR1 expression and MAIT-cell activation in lung cancer.

News Publication Date: August 18 (year not specified in the source).

Web References: Proceedings of the National Academy of Sciences; Johns Hopkins Kimmel Cancer Center; Bloomberg~Kimmel Institute for Cancer Immunotherapy.

References: Study published in Proceedings of the National Academy of Sciences; research supported by the Commonwealth Foundation and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.

Image Credits: Photo courtesy of Pakhi Birla.

Keywords: lung cancer, tumor microbiome, tumor-associated bacteria, vitamin B2, riboflavin metabolite, MR1, MAIT cells, cancer immunotherapy, antigen-presenting cells, immune response, Johns Hopkins, PNAS.